Business Insider

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven ...
Seeking Alpha

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

The abstracts will be available on the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics website. Following presentation, the posters will be available on the ...
Nasdaq

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for ...
BioWorld

Immuneering’s IMM-6-415 receives FDA clearance for phase I/IIa trial in solid tumors with RAF or RAS mutations

Immuneering Corp. has obtained FDA clearance of its IND application for IMM-6-415, an oral, twice-daily small molecule in development for the treatment of advanced RAF or RAS mutant solid tumors.